Reply  by Kaul, Sanjay et al.
REPLY
We appreciate the opportunity to clarify several of the statistical
issues raised by the SPORTIF studies. Our analysis (1) was
submitted for presentation at the American College of Cardiology
(ACC) scientific sessions in September 2004, a month before the
Food and Drug Administration’s (FDA) October 2004 review (2),
and a preliminary analysis indicating a high probability of ximel-
agatran being worse than warfarin was e-mailed to the principal
investigator (J.H.) on November 13, 2003.
1. The noninferiority margin. The statement by the investigators
that “There is more focus on the predefined delta than on the
results” ignores the International Conference on Harmoniza-
tion guidance (3) to the effect that the operative margin should
be pre-specified, founded on both “clinical judgment” and
“statistical reasoning,” and be “suitably conservative.” Instead,
SPORTIF’s margin appears to be chosen entirely on the basis
of expert consensus and was judged by the FDA as too liberal
(2). We stand by the more objective meta-analytic estimate in
our study (1).
2. The expected warfarin rate. SPORTIF’s rate of 3.1% is
inconsistent with 5 previous studies (1.9%) and the meta-
analysis described in the trial design (1.4%).
3. The relative noninferiority margin. Based on a conservative
estimate of the margin (1.44 relative risk [RR]), noninferiority
would have been established only for SPORTIF III, but not
for SPORTIF V.
4. Neglecting SPORTIF III. The warfarin event rate was twice
as high in SPORTIF III (open-label) compared to SPORTIF
V (double-blind) despite similar ximelagatran rates. We,
therefore, agree with the FDA that only the latter should be
considered pivotal to a judgment of efficacy (2). We did,
however, incorporate prior information from SPORTIF III in
our Bayesian meta-analysis.
5. Deleterious effects. Despite ximelagatran’s advantage in con-
venience and pharmacokinetics, it was associated with in-
creased hepatotoxicity, intolerability, and cost without clear
bleeding advantage. Analysis of noninferiority should ideally
be founded on 3 pre-requisite judgments—that the new
treatment 1) exhibits “therapeutic noninferiority” to the stan-
dard treatment, 2) would exhibit “therapeutic efficacy” in a
placebo-controlled trial, and 3) offers ancillary “nonefficacy
benefits” in safety, tolerability, convenience, or cost. We
hereby propose a composite score by which each of these
attributes is graded on a 0 (unestablished) to 1 (established)
scale. A score of 3 out of 3 thereby supports a judgment of
so-called virtual superiority to justify consideration of the new
over the standard treatment. As summarized in Table 1, virtual
superiority is not established for either of the SPORTIF trials
or for their combined analysis.
We agree that “balancing risks and benefits” should be integral
to the interpretation of clinical trials to avoid introduction of
suboptimal (and potentially harmful) treatments into routine
clinical practice. We hope that the suggestions outlined here
represent a small step in that direction. Of note, on February 14,
2006, AstraZeneca announced it had decided to withdraw ximel-
agatran from the worldwide market and terminate its development
(4). Res ipsa loquitur!
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Decompensated Heart Failure
and Diuretic Resistance
The study by Costanzo et al. (1) confirmed an observation from my
medical internship at The Peter Bent Brigham in 1952, but left an
unanswered question. Doctor Samuel Levine had admitted a
patient with severe edema of the feet and legs who was resistant to
mercurial diuretics. (She had been sitting upright in a chair that
increased the edema, but as Dr. Levine was fond of reminding us,
edema causes fewer symptoms when it is in the legs than in the
lungs.) He ordered Southey tubes, for me a novel concept. (The
term is still in my medical dictionary: small tubes inserted after
local anesthetics, facilitated by small nicks in the skin.) I was not
surprised to see the ultrafiltrate drain, but the big surprise was a
vigorous, general diuresis that followed with no other interven-
tions. I did not understand the mechanism until I read the report
by Costanzo et al. (1) stating that ultrafiltration by veno-venous
catheters also produced prolonged benefits due to decreased
neurohumeral activity, evidenced by a drop in B-type natriuretic
peptide (BNP) levels without worsening renal function.
Table 1. Composite Score for Grading the Quality of
Noninferiority Trials
Therapeutic
Noninferiority
Therapeutic
Efficacy
Nonefficacy
Benefit
Composite
Score
SPORTIF III 1 1 0 2
SPORTIF V 0 1 0 1
SPORTIF
IIIV
1 1 0 2
Criteria used for the attributes:
1. Therapeutic noninferiority: 95% upper bound of RR difference  clinically
acceptable and statistically justifiable marginal threshold (1.4 RR);
2. therapeutic efficacy: new treatment versus “imputed” placebo RR 1.0;
3. nonefficacy benefit: RR for safety and tolerability 1.0.
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